TY  - CONF

T1  - SOGUG-NEOWIN: A phase 2, open-label, multicenter, multinational interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and the combination of ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) harboring FGFR gene alterations.

JO  - Journal of Clinical Oncology

UR  - https://doi.org/10.1200/jco.2025.43.16_suppl.tps4628

PY  - 2025/06/01

AU  - de Velasco G

AU  - Necchi A

AU  - Loriot Y

AU  - Hussain SA

ED  - 

DO  - DOI: 10.1200/jco.2025.43.16_suppl.tps4628

PB  - American Society of Clinical Oncology (ASCO)

VL  - 43

IS  - 16_suppl

Y2  - 2025/12/05

ER  -